1. Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity
- Author
-
Lee Kyung Hong, David Sailer, Ajay S. Gulati, Imran S. Khan, Joshua Starmer, Pearl Bakhru, Lawrence Fong, Fengmin Zhao, Sandra J. Lee, Maureen A. Su, Stergios J. Moschos, Maria L. Mouchess, Meng-Lei Zhu, John M. Kirkwood, Mark S. Anderson, Yafei Hou, and Hsing-Hui Wang
- Subjects
0301 basic medicine ,CD4-Positive T-Lymphocytes ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,Cancer immunotherapy ,medicine.disease_cause ,Inbred C57BL ,Autoimmunity ,Mice ,0302 clinical medicine ,Monoclonal ,CTLA-4 Antigen ,Lymphocytes ,Melanoma ,Cancer ,Antibodies, Monoclonal ,General Medicine ,Autoimmune regulator ,Flow Cytometry ,3. Good health ,medicine.anatomical_structure ,5.1 Pharmaceuticals ,030220 oncology & carcinogenesis ,Central Tolerance ,Heterografts ,Immunotherapy ,Central tolerance ,Development of treatments and therapeutic interventions ,Research Article ,Biotechnology ,T cell ,Immunology ,Autoimmune Disease ,Antibodies ,03 medical and health sciences ,Lymphocytes, Tumor-Infiltrating ,Clinical Research ,medicine ,Animals ,Humans ,Tumor-Infiltrating ,business.industry ,Inflammatory and immune system ,Cellular immune response ,medicine.disease ,Immune checkpoint ,Blockade ,Mice, Inbred C57BL ,030104 developmental biology ,business ,Transcription Factors - Abstract
Blockade of immune checkpoint proteins (e.g., CTLA-4, PD-1) improves overall survival in advanced melanoma; however, therapeutic benefit is limited to only a subset of patients. Because checkpoint blockade acts by "removing the brakes" on effector T cells, the efficacy of checkpoint blockade may be constrained by the limited pool of melanoma-reactive T cells in the periphery. In the thymus, autoimmune regulator (Aire) promotes deletion of T cells reactive against self-antigens that are also expressed by tumors. Thus, while protecting against autoimmunity, Aire also limits the generation of melanoma-reactive T cells. Here, we show that Aire deficiency in mice expands the pool of CD4+ T cells capable of melanoma cell eradication and has additive effects with anti-CTLA-4 antibody in slowing melanoma tumor growth and increasing survival. Moreover, pharmacologic blockade of central T cell tolerance and peripheral checkpoint blockade in combination enhanced antimelanoma immunity in a synergistic manner. In melanoma patients treated with anti-CTLA-4 antibody, clinical response to therapy was associated with a human Aire polymorphism. Together, these findings suggest that Aire-mediated central tolerance constrains the efficacy of peripheral checkpoint inhibition and point to simultaneous blockade of Aire and checkpoint inhibitors as a novel strategy to enhance antimelanoma immunity.
- Published
- 2017